Shiyi Yu

521 total citations
21 papers, 335 citations indexed

About

Shiyi Yu is a scholar working on Molecular Biology, Oncology and Cancer Research. According to data from OpenAlex, Shiyi Yu has authored 21 papers receiving a total of 335 indexed citations (citations by other indexed papers that have themselves been cited), including 18 papers in Molecular Biology, 7 papers in Oncology and 5 papers in Cancer Research. Recurrent topics in Shiyi Yu's work include RNA Research and Splicing (5 papers), Ubiquitin and proteasome pathways (4 papers) and RNA modifications and cancer (3 papers). Shiyi Yu is often cited by papers focused on RNA Research and Splicing (5 papers), Ubiquitin and proteasome pathways (4 papers) and RNA modifications and cancer (3 papers). Shiyi Yu collaborates with scholars based in China, Singapore and Netherlands. Shiyi Yu's co-authors include Liming Chen, Yan Liu, Zhenghong Yu, Jean Paul Thiery, Lele Wu, Jun Zhang, Fei Ma, Chenxi Wu, Sheng Qin and Yuzhi Wang and has published in prestigious journals such as Journal of Biological Chemistry, Cancer Research and Oncogene.

In The Last Decade

Shiyi Yu

21 papers receiving 334 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Shiyi Yu China 12 257 97 67 49 33 21 335
Jeroen M. Bugter Netherlands 6 304 1.2× 102 1.1× 82 1.2× 38 0.8× 39 1.2× 6 411
Isabel Soria‐Bretones Canada 9 293 1.1× 126 1.3× 84 1.3× 57 1.2× 66 2.0× 10 378
Xingling Zheng China 9 322 1.3× 89 0.9× 95 1.4× 28 0.6× 38 1.2× 12 431
Lucia García-Gutiérrez Spain 9 305 1.2× 132 1.4× 62 0.9× 68 1.4× 27 0.8× 15 417
Hwajin Son South Korea 3 187 0.7× 116 1.2× 82 1.2× 37 0.8× 27 0.8× 4 290
Akito Nakamura Japan 8 326 1.3× 119 1.2× 56 0.8× 58 1.2× 31 0.9× 13 424
Sahar Mazhar United States 8 253 1.0× 73 0.8× 47 0.7× 31 0.6× 23 0.7× 9 322
Sophie Lehn Sweden 9 194 0.8× 155 1.6× 78 1.2× 63 1.3× 62 1.9× 10 337
Hexiu Su China 8 281 1.1× 107 1.1× 124 1.9× 64 1.3× 25 0.8× 11 383
Faying Xu China 4 289 1.1× 105 1.1× 115 1.7× 23 0.5× 41 1.2× 6 391

Countries citing papers authored by Shiyi Yu

Since Specialization
Citations

This map shows the geographic impact of Shiyi Yu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Shiyi Yu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Shiyi Yu more than expected).

Fields of papers citing papers by Shiyi Yu

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Shiyi Yu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Shiyi Yu. The network helps show where Shiyi Yu may publish in the future.

Co-authorship network of co-authors of Shiyi Yu

This figure shows the co-authorship network connecting the top 25 collaborators of Shiyi Yu. A scholar is included among the top collaborators of Shiyi Yu based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Shiyi Yu. Shiyi Yu is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Yu, Shiyi, et al.. (2025). The multifaceted roles of aldolase A in cancer: glycolysis, cytoskeleton, translation and beyond. Human Cell. 38(2). 45–45. 1 indexed citations
2.
Yu, Shiyi, et al.. (2025). Purine-rich element binding protein alpha: a DNA/RNA binding protein with multiple roles in cancers. Molecular Medicine. 31(1). 20–20. 2 indexed citations
3.
Yu, Shiyi, et al.. (2024). Alternative splicing of ALDOA confers tamoxifen resistance in breast cancer. Oncogene. 43(39). 2901–2913. 4 indexed citations
4.
Yu, Shiyi, Jianzhong Yu, Fei Cheng, et al.. (2024). SNRPB2 promotes triple‐negative breast cancer progression by controlling alternative splicing of MDM4 pre‐mRNA. Cancer Science. 115(12). 3915–3927. 2 indexed citations
5.
Yu, Shiyi, et al.. (2024). Utilizing a structure-based virtual screening approach to discover potential LSD1 inhibitors. Journal of Cancer Research and Clinical Oncology. 150(5). 253–253. 1 indexed citations
6.
Yu, Shiyi, et al.. (2024). Downregulation of the splicing regulator NSRP1 confers resistance to CDK4/6 inhibitors via activation of interferon signaling in breast cancer. Journal of Biological Chemistry. 301(1). 108070–108070. 1 indexed citations
7.
Khawar, Muhammad Babar, Shiyi Yu, Ali Afzal, & Haibo Sun. (2024). Unraveling the complex landscape of endocrine resistance in breast cancer: Emerging role of long noncoding RNA AGPG and beyond. Chinese Medical Journal. 137(16). 1985–1987. 1 indexed citations
8.
Yu, Shiyi, et al.. (2023). LncRNA AGPG Confers Endocrine Resistance in Breast Cancer by Promoting E2F1 Activity. Cancer Research. 83(19). 3220–3236. 23 indexed citations
9.
Yu, Shiyi, et al.. (2023). A Comprehensive Analysis Revealing FBXW9 as a Potential Prognostic and Immunological Biomarker in Breast Cancer. International Journal of Molecular Sciences. 24(6). 5262–5262. 3 indexed citations
10.
Su, Zhipeng, Ningning Zhou, Fugen Shangguan, et al.. (2021). Ciclopirox and bortezomib synergistically inhibits glioblastoma multiforme growth via simultaneously enhancing JNK/p38 MAPK and NF-κB signaling. Cell Death and Disease. 12(3). 251–251. 24 indexed citations
11.
Yu, Shiyi & Xinde Li. (2021). Gait-based Emotion Recognition Using Spatial Temporal Graph Convolutional Networks. 190–193. 3 indexed citations
12.
Liu, Yan, Shiyi Yu, Kuo‐Hsiang Huang, et al.. (2020). Protein Kinase D3 promotes the cell proliferation by activating the ERK1/c‐MYC axis in breast cancer. Journal of Cellular and Molecular Medicine. 24(3). 2135–2144. 18 indexed citations
13.
Yu, Shiyi, Xue Gong, Zhifang Ma, et al.. (2019). Endocrine resistant breast cancer cells with loss of ERα expression retain proliferative ability by reducing caspase7-mediated HDAC3 cleavage. Cellular Oncology. 43(1). 65–80. 17 indexed citations
14.
Liu, Yan, Yuzhi Wang, Shiyi Yu, et al.. (2019). The Role and Mechanism of CRT0066101 as an Effective Drug for Treatment of Triple-Negative Breast Cancer. Cellular Physiology and Biochemistry. 52(3). 382–396. 22 indexed citations
15.
Yu, Shiyi, Meng Zhang, Ling Huang, et al.. (2019). ERK1 indicates good prognosis and inhibits breast cancer progression by suppressing YAP1 signaling. Aging. 11(24). 12295–12314. 16 indexed citations
16.
Wu, Lele, Zhifang Ma, Yuzhi Wang, et al.. (2018). Transcriptional repressor GATA binding 1–mediated repression of SRY-box 2 expression suppresses cancer stem cell functions and tumor initiation. Journal of Biological Chemistry. 293(48). 18646–18654. 17 indexed citations
17.
Liu, Yan, Jun Zhang, Zhenghong Yu, et al.. (2017). Oncogenic Protein Kinase D3 Regulating Networks in Invasive Breast Cancer. International Journal of Biological Sciences. 13(6). 748–758. 13 indexed citations
18.
Yu, Shiyi, Chenxi Wu, Yan Liu, et al.. (2017). Targeting HSP90-HDAC6 Regulating Network Implicates Precision Treatment of Breast Cancer. International Journal of Biological Sciences. 13(4). 505–517. 49 indexed citations
19.
Yu, Shiyi, Chenxi Wu, Lele Wu, et al.. (2014). Adhesion glycoprotein CD44 functions as an upstream regulator of a network connecting ERK, AKT and Hippo-YAP pathways in cancer progression. Oncotarget. 6(5). 2951–2965. 53 indexed citations
20.
He, Xiaowen, Yu Xiao, Ting Liu, Shiyi Yu, & Daojin Chen. (2008). Vector-based RNA interference against vascular endothelial growth factor-C inhibits tumor lymphangiogenesis and growth of colorectal cancer in vivo in mice. Chinese Medical Journal. 121(5). 439–444. 20 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Jeroen M. Bugter Breakdown of academic impact, for papers by Isabel Soria‐Bretones Breakdown of academic impact, for papers by Xingling Zheng Breakdown of academic impact, for papers by Lucia García-Gutiérrez Breakdown of academic impact, for papers by Hwajin Son Breakdown of academic impact, for papers by Akito Nakamura Breakdown of academic impact, for papers by Sahar Mazhar Breakdown of academic impact, for papers by Sophie Lehn Breakdown of academic impact, for papers by Hexiu Su Breakdown of academic impact, for papers by Faying Xu
Rankless by CCL
2026